BeStock  

Cooper Companies COO

US equityMarket cap rank #1319Medical Instruments & Supplies
$58.88 −$1.45 (-2.40%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $59.53 +1.10%
Open$60.67
Prev close$60.33
Day range$58.66 – $60.98
Volume2.08M
Market cap$11.20B
P/E (TTM)20.2
Dividend yield–
Founded1980
CEOMr. Albert G. White, III
Employees15,000
HeadquartersSan Ramon, United States of America
Websitewww.coopercos.com

Revenue per employee

$197.0K$224.1K$251.3K$278.4KOct '18Oct '21Oct '25

15,000 employees as of 2025/FY (-6.3% YoY). Revenue per employee is total revenue divided by headcount — a rough productivity gauge, not a per-worker pay figure.

Management team

Albert G. White, III Director, President and Chief Executive Officer
Age 56 · Total comp. $16,051,141.00 · As of 23 Feb 2026
Background

Mr. White has served as President & Chief Executive Officer and as a member of our Board of Directors since May 2018. Under his leadership, CooperCompanies has developed into a unified, synergistic operating company and global medical device leader - driving strong revenue and profit growth through organizational evolution while elevating CooperVision to the world's #1 contact lens company by wearers and CooperSurgical to the global leader in fertility devices and a U.S. leader in high-risk labor and delivery safety. Prior to his appointment as CEO, Mr. White served in various leadership roles across CooperCompanies, developing an intimate understanding of the business and its markets. He served as Chief Financial Officer from November 2016 to May 2018 and as EVP and Chief Strategy Officer beginning in 2015 and 2011, respectively. From August 2015 to May 2018, he also led the Company's women's healthcare business and served as CEO of Cooper Medical Inc., the parent company of CooperSurgical. Earlier in his tenure at CooperCompanies, he held the roles of VP, Investor Relations (2007-2013) and VP and Treasurer (2006-2012). Before joining CooperCompanies, Mr. White spent three years as a Director at KeyBanc Capital Markets and held numerous positions of increasing responsibility within KeyBank National Association over the prior eight years. Mr. White also serves as a member of the Board of Directors of Evolus, Inc. (NASDAQ: EOLS), a performance beauty company building an aesthetic portfolio of consumer brands. He is Chair of the Compensation Committee and a member of the Audit Committee. Mr. White holds a B.S. in Finance and an MBA, both from Virginia Tech.

Daniel G. McBride, Esq. Executive Vice President, Chief Operating Officer, General Counsel and Corporate Secretary
Age 61 · Total comp. $4,823,031.00 · As of 23 Feb 2026
Background

Mr. McBride has served as Executive Vice President and Chief Operating Officer since November 2013. He previously served as the President of CooperVision, Inc., our contact lens subsidiary, from February 2014 through February 2022, as our Chief Risk Officer from July 2011 through October 2013, as our General Counsel from November 2007 through January 2014, and as Vice President from July 2006 through October 2013. He also served as Senior Counsel from February 2005 through November 2007. Prior to joining the Company, Mr. McBride was an attorney with Latham & Watkins LLP from October 1998 to February 2005, concentrating on mergers and acquisitions and corporate finance matters. Mr. McBride holds a B.S. in Finance from Santa Clara University and a J.D. from Stanford Law School.

Brian G. Andrews Principal Accounting Officer, Executive Vice President, Chief Financial Officer and Treasurer
Age 46 · Total comp. $4,337,663.00 · As of 11 Dec 2025
Background

On December 9, 2025, Brian G. Andrews, Executive Vice President, Chief Financial Officer and Treasurer of The Cooper Companies, Inc., assumed the role of principal accounting officer of the Company. Mr. Andrews has served as Executive Vice President, Chief Financial Officer and Treasurer since December 2020. He previously served as our Senior Vice President, Chief Financial Officer & Treasurer from May 2018, and as Treasurer since January 2013 and Vice President since November 2014. He also served as Vice President, Global Logistics and Service for CooperSurgical, a position he held from June 2017 to May 2018. Mr. Andrews previously served as Assistant Treasurer for the Company from April 2006 to December 2012. Prior to joining the Company, he held various corporate and investment banking positions at KeyBanc Capital Markets from 2002 to 2006 and at ING Barings from 2000 to 2001. Mr. Andrews holds a B.A. in Economics from Columbia University.

Holly R. Sheffield President, CooperSurgical, Inc.
Age 55 · Total comp. $3,656,688.00 · As of 23 Feb 2026
Background

Ms. Sheffield has served as President of CooperSurgical, Inc., our women's healthcare business, since July 2020. Previously, she served as Executive Vice President & Chief Strategy Officer from June 2018 to July 2020. Prior to joining the Company, Ms. Sheffield had over 20 years of experience in investment banking. She joined Cooper from UBS Securities LLC, where she was a Managing Director, Global Head of Medical Technology from 2009 to May 2018. From 2000 to 2009, Ms. Sheffield was at Credit Suisse and from 1997-2000, Ms. Sheffield was at Donaldson, Lufkin & Jenrette until it was acquired by Credit Suisse. She received a B.S. from Cornell University and an M.B.A. from Columbia Business School.

Gerard H. Warner, III President, CooperVision, Inc.
Age 61 · Total comp. $3,644,828.00 · As of 23 Feb 2026
Background

Mr. Warner has served as President, CooperVision, Inc. from February 2022. He previously served as Executive Vice President, Americas & Global Commercial Functions of CooperVision from April 2019 to January 2022 and as President, Americas from May 2015 to March 2019. Mr. Warner served in various other Vice President and Senior Vice President positions with CooperVision from May 2012 through April 2015. Prior to joining CooperVision, Mr. Warner spent 17 years at Bausch + Lomb in a variety of marketing and management roles. Mr. Warner earned a B.S. in Business Administration in Marketing from Villanova University and an M.B.A. from The Simon School of Business, University of Rochester.

Teresa S. Madden Independent Director
Age 70 · Total comp. $359,979.00 · As of 23 Feb 2026
Background

Ms. Madden is an accomplished financial executive and active CPA with more than three decades of public company experience, having led all finance functions as CFO of a Fortune 300 company and through additional financial oversight through her service on public company audit committees. Ms. Madden served as EVP and Chief Financial Officer of Xcel Energy, Inc. (NASDAQ: XEL) from 2011 to until her retirement in 2016 with responsibility for all financial functions, including controllership, treasury, tax, risk management, internal audit, budgeting and forecasting, investor relations, regulatory revenue requirements, and corporate development. At Xcel, Ms. Madden was directly responsible for managing an annual capital investment spend in excess of $3 billion and external financing requirements ranging from $1-$2 billion. From 2004 to 2011, she served as VP, Controller & Principal Accounting Officer, and from 2003 to 2004 as VP of Finance for Customer & Field Operations. Prior to these roles, she served as Corporate Controller & Interim Chief Financial Officer at Rogue Wave Software from 2000 to 2003, Corporate Controller & Principal Accounting Officer at New Century Energies from 1997 to 2000 and held progressively senior financial positions at Public Service Company of Colorado from 1979 to 1997. Ms. Madden serves on the board of Enbridge, Inc. (NYSE: ENB) and serves on the governance committee and as chair of the audit, finance and risk committee. She previously served as a director for Peabody Energy Corporation (NYSE: BTU) from 2017 to 2020 where she served on the health, safety, security & environmental committee and as chair of the audit committee. She holds a B.S. in Accounting from Colorado State University and an MBA from Regis University and maintains an active Colorado CPA license.

Colleen E. Jay Chairman of the Board
Age 62 · Total comp. $354,979.00 · As of 3 Dec 2025
Background

The Board appointed Colleen E. Jay as Chairman, effective immediately as Chairman on January 2, 2026. Ms. Jay served as a Global Division President for Procter and Gamble until her retirement in October 2017. Her most recent operational assignment was President, Global Beauty Specialty Business at Procter & Gamble from 2015 where she was responsible for the Wella Professional Salon, Cosmetics, Retail Hair Color, and Fragrance businesses, and the successful divestiture of them. Prior to that, Ms. Jay led the multi-billion dollar Global Retail Hair Care and Color division of Procter & Gamble from 2012 to 2015 and the Global Female Beauty division from 2010 to 2012. She also served as Vice President & General Manager, Greater China Feminine Care, Personal Cleansing, Oral Care & Entire China Marketing Function, based in Guangzhou, China, from 2006 to 2009, where she was responsible for businesses with a combined value of over 1 Billion. She worked in various positions with Procter & Gamble since July 1985 and has led operational units in the United States, Canada, China, and Switzerland (including leading global businesses) during the course of her career. Ms. Jay has also volunteered at Catalyst, Inc., a non-profit organization dedicated to improving workplace inclusion for women. She graduated with honors from Wilfrid Laurier University with a bachelor's degree in business administration. Other Public Company Boards: Treasury Wine Estates and Beyond Meat, Inc.

Cynthia L. Lucchese Independent Director
Age 65 · Total comp. $348,729.00 · As of 23 Feb 2026
Background

Ms. Lucchese brings over 30 years of senior corporate leadership, including nearly 20 years as a CFO, with deep expertise in strategy, M&A, international business, finance, and accounting, complemented by extensive board and governance experience across numerous healthcare and medical device companies. Ms. Lucchese served as Chief Strategy Officer for Penske Entertainment Corp from 2020 until her retirement in 2023. From 2014 to 2020, she was Chief Administrative Officer and Chief Financial Officer where she worked on the sale of Hulman and Company to Roger Penske. Previously, she served as SVP and Chief Financial Officer of Hillenbrand (NYSE: HI) from 2008 to 2014. Prior, Ms. Lucchese was SVP and Chief Financial Officer of Thoratec from 2005 to 2007. She also held various senior financial roles at Guidant Corporation (NYSE: GDT) from 1994 to 2005. Ms. Lucchese is a member of the board of BVI Medical, a private global ophthalmic device company, and serves as chair of the audit committee. She is a member of the board of Microtransponder, a private medical device company focused on chronic stroke recovery and serves as chair of the audit committee. Ms. Lucchese previously served on the board of Inari Medical, a company focused on the treatment of venous thromboembolism and other venous diseases, from 2019 until its acquisition by Stryker in 2025, where she chaired the nominating & corporate governance committee and the audit committee. She also served on the board of Relievant Medsystems, Inc., a private medical device company, from 2022 until its sale to Boston Scientific in 2023, where she was chair of the audit committee. Ms. Lucchese also served on the board of Hanger, Inc., a provider of orthotic and prosthetic care services and products, until its acquisition in 2022 by Patient Square Capital, where she served on the audit and compensation committees, and on the board of Intersect ENT from 2014 until its acquisition by Medtronic, Inc. in 2022, where she served as chair of the audit committee and a member of the nominating & corporate governance committee. Ms. Lucchese served on the Board of Trustees for Indiana University from 2021 to 2025, as vice chair of the board and chair of the finance and audit committee. Ms. Lucchese holds a B.S. in Accounting and MBA from the Indiana University Kelley School of Business.

Dr. Maria Rivas, M.D. Independent Director
Age 62 · Total comp. $334,979.00 · As of 23 Feb 2026
Background

Dr. Rivas is a highly accomplished physician executive and public-company board director with more than 25 years of global experience advancing medical devices and pharmaceutical products, offering a clinically grounded, data-driven perspective on innovation, regulatory strategy, and long-term growth. From 2022 to 2025, Dr. Rivas served as Global Chief Medical Officer and Head of Evidence Generation for Pfizer, Inc. (NYSE: PFE), where she managed global operations of several thousand data scientists, healthcare experts, and field staff, oversaw the launch of multiple medical products, and led a digital transformation to optimize product launches and market growth and improve research capabilities. Prior to her role at Pfizer, she served as Chief Medical Officer and SVP for the healthcare business of Merck KGaA (which operates as EMD Serono in the US and Canada) from 2019 to 2022, where she led the Global Pharmacovigilance, Medical Affairs and Evidence and Value Development (HEOR) teams in over 90 countries. Prior to that, Dr. Rivas served as SVP of Global Medical Affairs at Merck & Co (also dba MSD), as VP of Global Medical Affairs at AbbVie (NYSE: ABBV), as VP of Oncology, General Medicine and Diagnostic Imaging Medical Affairs at Bayer Healthcare, and in various roles at Eli Lilly including Head of US Women's Health Medical Affairs. Before joining Eli Lilly, Dr. Rivas was in private practice as an endocrinologist in Puerto Rico. Dr. Rivas served as a director for Medidata (NASDAQ: MDSO), a public, mid-cap health technology company, until its merger with Dassault Systemes, and served as a member of the audit and compensation committees. Dr. Rivas holds a B.A. in Biochemistry from Brandeis University and an M.D. from Columbia University's Vagelos College of Physicians and Surgeons. She completed a residency in internal medicine and a fellowship in endocrinology at New York Presbyterian Hospital and is board certified in endocrinology, diabetes, and metabolism.

Lawrence E. Kurzius Independent Director
Age 68 · Total comp. $334,979.00 · As of 23 Feb 2026
Background

Mr. Kurzius is a highly respected global business leader who brings extensive public company leadership, including as CEO, and experience in long-range strategic planning, consumer marketing, human capital management, and enterprise risk management, and has demonstrated a strong record of driving performance and sustained growth throughout his career leading multinational organizations. Mr. Kurzius served as the Chief Executive Officer of McCormick & Company, Incorporated (NYSE: MKC) from 2016 to 2023 and as its President from 2015 to 2022. While he was CEO, the company more than doubled its market value. He previously held roles of increasing responsibility at McCormick, including President and Chief Operating Officer from 2015 to 2016, President of McCormick's global consumer business from 2013 to 2016, Chief Administrative Officer from 2013 to 2015, President of the international business from 2008 to 2013, and President of EMEA from 2007 to 2008. Previously, Mr. Kurzius was the Chief Executive Officer of Zatarain's, where he worked for 12 years before the company was acquired by McCormick. Prior to this, Mr. Kurzius was a marketing executive with the Quaker Oats Company and Mars Inc.'s Ben's Original (formerly Uncle Ben's). Mr. Kurzius currently serves as the Chairman of the Board of Elanco Animal Health Inc. (NYSE: ELAN) since 2024; he has served as a member of its board as well as on its corporate governance committee, audit committee and as chair of its compensation and human capital committee since 2018. He also serves on the board of Lamb Weston (NYSE: LW), as well as on its compensation and human capital committee and nominating and corporate governance committee, since July 2025. Mr. Kurzius previously served as a member of the board of McCormick until 2025, as the Executive Chairman from 2023 to 2024 and as the Chairman from 2017 to 2023. Mr. Kurzius holds an A.B. in economics from Princeton University, graduating magna cum laude.

Barbara A. Carbone Independent Director
Age 67 · Total comp. $279,977.00 · As of 23 Feb 2026
Background

Ms. Carbone is a seasoned audit leader with nearly 40 years of experience advising global companies across the medical device, manufacturing, and technology sectors, bringing strong financial oversight and deep familiarity with CooperCompanies from more than two decades supporting its audit in various roles. Ms. Carbone served as an Audit Partner at KPMG LLP until her retirement in 2019. She served on the KPMG Partnership Audit Committee for six years, including three years as the chairperson, and as the National Partner in Charge of Human Resources for the Audit Practice. In this role, Ms. Carbone co-led the strategic centralization of HR and its practices and policies firmwide, including the design and implementation of global performance management processes, compensation strategy, and succession planning. Ms. Carbone serves as a member of the board of directors, chair of the audit & finance committee, and member of the compensation committee of Limoneira Company (NASDAQ: LMNR). She also serves on the board of directors and is chair of the audit committee of Bob's Discount Furniture (NYSE: BOBS). Ms. Carbone served as board chair, audit committee chair and member of the compensation and workforce committee at TrueCar, Inc. (NASDAQ: TRUE) from August 2020 until its sale in 2026. She also served on the board of directors, as a member of the audit committee, and as chair of both the compensation committee and nominating & corporate governance committee of DZS, Inc. (NASDAQ: DZSI) from 2021 through 2025. From 1998 through 2019, she served as a member of the board of directors and chair of the audit committee of the Women's Business Enterprise National Council, and from 2008 through 2023, she served on the board of trustees of the Exploratorium, a museum of science, technology, and arts in San Francisco. She holds a B.S. in Business Administration (Accountancy) from California State University at Sacramento. Ms. Carbone was recommended for nomination to the Board by the CGNC.

Paul A. Keel Independent Director
As of 3 May 2026
Background

On May 4, 2026, The Cooper Companies, Inc. announced that, the Board of Directors of the Company approved the appointment of Paul Keel to fill the new director position, effective as of July 1, 2026. Mr. Keel has served as President and Chief Executive Officer of Envista Holdings Corporation (NYSE: NVST), a global specialty medical technology company, since 2024. Prior to joining Envista, Mr. Keel served as CEO of Smiths Group plc (LON: SMIN), a diversified global industrial technology company and FTSE constituent, from 2021 to 2024. Earlier, he spent 16 years at 3M, serving in various leadership roles, including Group President of 3M Consumer Business, President of 3M Medical, President of 3M Unitek, SVP of Manufacturing & Supply Chain, and SVP of Marketing, Sales & Business Development. Mr. Keel's career also includes roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College.

Walter M Rosebrough, Jr Independent Director
Age 71 · As of 23 Feb 2026
Background

The Board appointed Mr. Rosebrough to the Board, effective January 3, 2026. Mr. Rosebrough brings experience driving significant growth and shareholder returns during his 40+ years in the healthcare industry, including 25 years as CEO in medical devices, having led organizations from startups to multi-billion-dollar global enterprises and functions across product development, M&A, marketing, manufacturing, and finance. Mr. Rosebrough currently serves as CEO Emeritus and Senior Advisor of STERIS plc (NYSE: STE), a global medical device business focused on infection prevention products and services. During his tenure as CEO of STERIS from 2007 to 2021, STERIS's shareholders received an 18% annualized return compared with 10% for the S&P 500, and the company's market capitalization increased from $2 billion to $20 billion. His career also includes nearly two decades at Hill-Rom (purchased by Baxter (NYSE: BAX), a global leader in patient support systems, therapeutic products, and workflow information technology where he held senior executive positions, including President and CEO of Support Systems International and President and CEO of Hill-Rom. Mr. Rosebrough has served on several healthcare industry boards, including the Association for the Advancement of Medical Instrumentation (AAMI), where he currently serves as chair; the Advanced Medical Technology Association (AdvaMed), where he was a member of the executive committee and chair of the compensation and finance committees; and the Medical Device Manufacturers Association. Mr. Rosebrough currently serves as independent chair of the board of Varex Imaging (NASDAQ: VREX), and independent member of the board of Precipart, a private company. Mr. Rosebrough holds an MBA from Stanford University, and a BIE from Kettering University.

Walter M. Rosebrough, Jr Independent Director
As of 22 Dec 2025
Background

On December 22, 2025, the Board appointed Mr. Rosebrough to the Board, effective January 3, 2026. Mr. Rosebrough currently serves as CEO Emeritus and Senior Advisor of STERIS plc (NYSE: STE), a global medical device business focused on infection prevention products and services. During his tenure as CEO of STERIS from 2007 to 2021, STERIS's stock generated a 10-fold total return or an 18% annualized return compared with a 10% annualized return for the S&P 500, and the company's market capitalization increased by over $20 billion. His career also includes nearly two decades at Hill-Rom Holdings, Inc., where he held senior executive positions, including President and CEO of Support Systems International and President and CEO of Hill-Rom. Mr. Rosebrough currently serves as Independent Chair on the Board of Varex Imaging.

Agostino Ricupati Senior Vice President, Finance and Tax
Age 58 · As of 11 Dec 2025
Background

Mr. Ricupati has served as our Chief Accounting Officer since October 2017 and as Senior Vice President, Finance & Tax since July 2017. Mr. Ricupati previously served as Vice President, Tax for the Company from July 2013 to July 2017. Prior to joining the Company, he served as International Tax Director for Intel Corp. from 2010 to 2013 and in various other senior finance and tax positions over the past 20 years. Mr. Ricupati holds a master's degree from DePaul University and is a Certified Public Accountant. Agostino Ricupati will continue in the role of the Company's Senior Vice President, Tax and cease as principal accounting officer effective December 9, 2025.

From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.

Sectors & themes

Discussion

No comments yet — be the first to weigh in on COO.

Sign in to join the discussion.

Scroll to Top